Gapping up
In reaction to earnings/guidance:
- INMD +5.1%, PRCT +4.1%, ICLR +3.3%, VAPO +3%, IART +2.7% (guides Q4 revs slightly above consensus; also announces $125 share repurchase authorization), .
Other news:
- DNA +7.2% (expects to meet or exceed 2021 performance targets)
- SRLP +5.5% (receives takeover proposal at $16.50/unit)
- ATAI +3.9% (announces FDA Investigational New Drug (IND) clearance for PCN-101 R-ketamine program)
- PSTL +3.7% (provides an update on its portfolio)
- MFG +3.6% (acquires Capstone Partners)
- ALLY +2.6% (approves $2 bln share repurchase program; also increases dividend)
- RDFN +2.3% (to acquire Bay Equity Home Loans for $135 in cash and stock)
- CROX +2% (CEO appears on CNBC: says Wall Street may not fully appreciate HeyDude acquisition)
- PEI +1.7% (reports holiday traffic and progress on key strategic initiatives)
- X +1.3% (announces new steel production facility)
- APAM +1.3% (reports December AUM)
Analyst comments:
- WOLF +4.3% (upgraded to Overweight from Equal Weight at Wells Fargo)
- LC +3% (upgraded to Buy from Neutral at Janney)
- LAC +2.8% (upgraded to Outperform from Market Perform at Cowen)
- AMBA +2.7% (upgraded to Overweight from Equal Weight at Wells Fargo)
- DASH +2.4% (upgraded to Outperform from In-line at Evercore ISI)
- SNOW +2.4% (upgraded to Overweight from Equal Weight at Barclays)
- TTWO +1.4% (upgraded to Outperform from Market Perform at BMO Capital Markets)
- WFC +1% (upgraded to Overweight from Neutral at Piper Sandler)